Synergistic compositions and method of use

Claim 3

The method of claim 1, wherein M is magnesium, Y is sulfate and t is 1.

Claim 4

The method of claim 1, wherein M is calcium, Y is chloride and t is 2.

Claim 5

The method of claim 1, wherein M is calcium, magnesium or barium.

Claim 6

The method of claim 1, wherein the formula is selected from the group consisting of (C 5 H 4 NOS) 2 CaCl 2 , (C 5 H 4 NOS) 2 MgSo 4 , (C 5 H 4 NOS) 2 SrCl 2 , (C 5 H 4 NOS) 2 SrBr 2 , (C 5 H 4 NOS) 2 Ca(NO 3 ) 2 and (C 5 H 4 NOS) 2 Ba(ClO 3 ) 2 .

Claim 7

The method of claim 1, wherein said warm blooded animal is treated for skin conditions requiring anti-inflammatory treatment.

Claim 8

The method of claim 6, wherein said skin condition is contact dermatitis, seborrheic dermatitis, atopic dermatitis or neuro dermatitis.

Claim 9

The method of claim 1, wherein said adducts are water-soluble.

Claim 10

The method of claim 1, wherein Y is selected from the group consisting of halides, sulfates, nitrates and acetates.

Claim 15

A composition for topically treating inflammation in warm blooded animals which comprises about 0.05 to about 5% by weight of the total composition of the combination of a non-steroidal anti-inflammatory agent selected from the group consisting of 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid, d-2-(6-methoxy-2-naphthyl) propionic acid, 1-methyl-5-(4-methylbenzoyl-1 H-pyrrole)-2-acetic acid, α-methyl-4-(2-methylpropyl)benzeneacetic acid, 4-(2-methylpropyl) benzeneacetic acid, α-methyl-3-phenoxybenzeneacetic acid, α,3-dichloro-4-cyclohexylphenylacetic acid and 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid and the adducts of bis-([-]2-pyridyl-1-oxide) disulfide having the empirical formula: (C.sub.5 H.sub.4 NOS).sub.2 MY.sub.t (I) wherein M represents a member selected from the group consisting of zinc, iron, magnesium, tin, cadmium, zirconium, alkali and alkaline earth metals; Y is the anion of an inorganic or organic acid and t is either 1 or 2, together with a suitable pharmaceutical carrier, said non-steroidal anti-inflammatory agent being present in the amount of 1-40% by weight of said adduct.

Claim 16

A composition for topically treating inflammation in warm blooded animals which comprises about 0.05 to about 5% by weight of the total composition of the combination of a non-steroidal anti-inflammatory agent selected from the group consisting of 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid, d-2-(6-methoxy-2-naphthyl) propionic acid, 1-methyl-5-(4-methylbenzoyl-1 H-pyrrole)-2-acetic acid, α-methyl-4-(2-methylpropyl)benzeneacetic acid, 4-(2-methylpropyl) benzeneacetic acid, α-methyl-3-phenoxybenzeneacetic acid, α,3-dichloro-4-cyclohexylphenylacetic acid and 2',4'-difluoro-4-hydroxy-3-biphenylcarboxylic acid and the adducts of bis-([-]2-pyridyl-1-oxide) disulfide having the empirical formula: (C.sub.5 H.sub.4 NOS).sub.2 MY.sub.t (I) wherein M represents a member selected from the group consisting of zinc, iron, magnesium, tin, cadmium, zirconium, alkali and alkaline earth metals; Y is the anion of an inorganic or organic acid and t is either 1 or 2, together with a suitable pharmaceutical carrier, said non-steroidal anti-inflammatory agent being present in the amount of 1-40% by weight of said adduct.

Claim 17

A composition for topically treating inflammation in warm blooded animals which comprises about 0.05 to about 5% by weight of the total composition of the combination of 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid and the adducts of bis-([≡]2-pyridyl-1-oxide) disulfide having the empirical formula: (C.sub.5 H.sub.4 NOS).sub.2 MY.sub.t (I) wherein M represents a member selected from the group consisting of zinc, iron, tin, cadmium, magnesium, zirconium, alkali and alkaline earth metals; Y is the anion of an inorganic or organic acid and t is either 1 or 2, together with a suitable pharmaceutical carrier, said 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid being present in the amount of 1-40% by weight of said adduct.

Claim 18

A composition for topically treating inflammation in warm blooded animals which comprises about 0.05 to about 5% by weight of the total composition of the combination of 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid and the adducts of bis-([≡]2-pyridyl-1-oxide) disulfide having the empirical formula: (C.sub.5 H.sub.4 NOS).sub.2 MY.sub.t (I) wherein M represents a member selected from the group consisting of zinc, iron, tin, cadmium, magnesium, zirconium, alkali and alkaline earth metals; Y is the anion of an inorganic or organic acid and t is either 1 or 2, together with a suitable pharmaceutical carrier, said 1-(p-chlorobenzoyl)-5-methoxy-2-methylindole-3-acetic acid being present in the amount of 1-40% by weight of said adduct.

Claim 19

The composition of claim 13, wherein M is magnesium, Y is sulfate and t is 1.

Claim 20

The composition of claim 13, wherein M is calcium, Y is chloride and t is 2.

Claim 21

The composition of claim 13, wherein M is calcium, magnesium or barium.

Claim 22

The composition of claim 13, wherein the formula is selected from the group consisting of (C 5 H 4 NOS) 2 CaCl 2 , (C 5 H 4 NOS) 2 MgSO 4 , (C 5 H 4 NOS) 2 SrCl 2 , (C 5 H 4 NOS) 2 SrBr 2 , (C 5 H 4 NOS) 2 Ca(NO 3 ) 2 and (C 5 H 4 NOS) 2 Ba(ClO 3 ) 2 .

Claim 23

The composition of claim 13, wherein said adducts are water-soluble.

Claim 24

The composition of claim 13, wherein Y is selected from the group consisting of halides, sulfates, nitrates and acetates.

Claim 25

A composition for topically treating inflammation in warm blooded animals comprising as active agents the combination of α,3-dichloro-4-cyclohexylphenylacetic acid and bis-(2-pyridyl-1-oxide) disulfide magnesium sulfate and a suitable pharmaceutical carrier, said active agents being present in said composition in an amount of 0.05-10% by weight of composition and said α,3-dichloro-4-cyclohexylphenylacetic acid being present in an amount of 1-40% by weight of bis-(2-pyridyl-1-oxide) disulfide magnesium sulfate.

Claim 26

A composition for topically treating inflammation in warm blooded animals comprising as active agents the combination of α,3-dichloro-4-cyclohexylphenylacetic acid and bis-(2-pyridyl-1-oxide) disulfide magnesium sulfate and a suitable pharmaceutical carrier, said active agents being present in said composition in an amount of 0.05-10% by weight of composition and said α,3-dichloro-4-cyclohexylphenylacetic acid being present in an amount of 1-40% by weight of bis-(2-pyridyl-1-oxide) disulfide magnesium sulfate.